NewAmsterdam Pharma Company N.V. achieved a significant regulatory achievement on September 21 when the European Commission approved Ubeslo and Evlarco, marking the first global approvals for these cholesterol-reduction treatments. Ubeslo contains 10 mg of obicetrapib, while Evlarco combines 10 mg of obicetrapib with 10 mg of ezetimibe. Both medicines are intended for adults managing primary high cholesterol or mixed lipid disorders.
The treatments target low-density lipoprotein cholesterol reduction among patients already receiving maximum tolerated cholesterol therapy. Clinical trial data demonstrated statistically significant LDL-C reductions of up to 40% with obicetrapib monotherapy and approximately 50% with the combination across the Phase 3 program. The oral formulation may offer convenience advantages for patients requiring additional cholesterol management.
Menarini holds exclusive commercialization rights across Europe, with NewAmsterdam Pharma entitled to tiered royalties ranging from low double-digit percentages to the mid-20% range on net sales. The agreement also includes potential clinical, regulatory, and commercial milestone payments totaling up to €833 million, contingent on specified achievements. As of June 30, 2026, the company maintained $678.3 million in cash, cash equivalents, and marketable securities.
Several factors remain unresolved regarding commercial viability. The company did not disclose launch prices or project royalty revenue figures. Reimbursement decisions, prescribing restrictions, and negotiated prices will ultimately determine patient access and the net sales supporting royalties. Additionally, the ongoing PREVAIL cardiovascular-outcomes trial, which enrolled more than 9,500 patients, is designed to evaluate whether obicetrapib reduces major cardiovascular events, with an interim analysis planned for the fourth quarter of 2026 and results expected in the first quarter of 2027.
NewAmsterdam Pharma continued reporting substantial research and development expenses of $41.7 million in the second quarter, with a net loss of $64.1 million. The company faces the dual challenge of managing development spending while preparing for European commercialization, and regulatory approval does not establish near-term profitability. The transition from approval to sustainable revenue generation will depend on successful reimbursement negotiations, prescriber adoption, and cardiovascular outcome data.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI